These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis. Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991 [TBL] [Abstract][Full Text] [Related]
6. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related? de Bortoli N; Nacci A; Savarino E; Martinucci I; Bellini M; Fattori B; Ceccarelli L; Costa F; Mumolo MG; Ricchiuti A; Savarino V; Berrettini S; Marchi S World J Gastroenterol; 2012 Aug; 18(32):4363-70. PubMed ID: 22969200 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of gastroesophageal reflux disease in Moscow. Bor S; Lazebnik LB; Kitapcioglu G; Manannikof I; Vasiliev Y Dis Esophagus; 2016; 29(2):159-65. PubMed ID: 25604401 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of symptoms and use of medication for gastroesophageal reflux in an Australian community. Watson DI; Lally CJ World J Surg; 2009 Jan; 33(1):88-94. PubMed ID: 18949510 [TBL] [Abstract][Full Text] [Related]
9. The Prevalence and Clinical Features of Non-responsive Gastroesophageal Reflux Disease to Practical Proton Pump Inhibitor Dose in Korea: A Multicenter Study. Park HJ; Park SH; Shim KN; Kim YS; Kim HJ; Han JP; Kim YS; Bang BW; Kim GH; Baik GH; Kim HH; Park SY; Kim SS Korean J Gastroenterol; 2016 Jul; 68(1):16-22. PubMed ID: 27443619 [TBL] [Abstract][Full Text] [Related]
10. [Application of the recommendations of the conference of consensus in front of symptoms ENT, respiratory or thoracic pains considered as due to a gastroesophageal reflux disease]. Vallot T; Ducrotte P; Bour B; Jacques JP; Houcke P; De Korwin JD; Pariente A; Aygalenq P; Coudsy B; Carrois F; Ricci L; Bruley des Varannes S Presse Med; 2013 May; 42(5):e125-32. PubMed ID: 23414966 [TBL] [Abstract][Full Text] [Related]
11. Treatment of gastroesophageal reflux disease. Pettit M Pharm World Sci; 2005 Dec; 27(6):432-5. PubMed ID: 16341949 [TBL] [Abstract][Full Text] [Related]
12. Medical Treatment of Gastroesophageal Reflux Disease. Kroch DA; Madanick RD World J Surg; 2017 Jul; 41(7):1678-1684. PubMed ID: 28321555 [TBL] [Abstract][Full Text] [Related]
13. Unmet treatment needs of gastroesophageal reflux disease in Asia: gastroesophageal reflux disease in Asia Pacific survey. Goh KL; Choi MG; Hsu WP; Chun HJ; Mahachai V; Kachintorn U; Leelakusolvong S; Kim N; Rani AA; Wong BC; Wu J; Chiu CT; Chu R; Shetty V; Bocobo JC; Chan MM; Lin JT J Gastroenterol Hepatol; 2014 Dec; 29(12):1969-75. PubMed ID: 24990817 [TBL] [Abstract][Full Text] [Related]
14. [Gastroesophageal Reflux Disease]. Park CH; Lee SK Korean J Gastroenterol; 2019 Feb; 73(2):70-76. PubMed ID: 30845382 [TBL] [Abstract][Full Text] [Related]
15. Current Trends in the Management of Gastroesophageal Reflux Disease. Sandhu DS; Fass R Gut Liver; 2018 Jan; 12(1):7-16. PubMed ID: 28427116 [TBL] [Abstract][Full Text] [Related]
16. Mucosal Protective Compounds in the Treatment of Gastroesophageal Reflux Disease. A Position Paper Based on Evidence of the Romanian Society of Neurogastroenterology. Surdea-Blaga T; Băncilă I; Dobru D; Drug V; Frățilă O; Goldiș A; Grad SM; Mureșan C; Nedelcu L; Porr PJ; Sporea I; Dumitrascu DL J Gastrointestin Liver Dis; 2016 Dec; 25(4):537-546. PubMed ID: 27981311 [TBL] [Abstract][Full Text] [Related]
17. Gastroesophageal reflux disease prevalence in the city of Sivas. Yönem Ö; Sivri B; Özdemir L; Nadir I; Yüksel S; Uygun Y Turk J Gastroenterol; 2013; 24(4):303-10. PubMed ID: 24254260 [TBL] [Abstract][Full Text] [Related]
18. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China. Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097 [TBL] [Abstract][Full Text] [Related]